Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Ultragenyx Pharmaceutical Analyst Ratings and Price Targets | NASDAQ:RARE | Benzinga
Ultragenyx Pharmaceutical Inc has a consensus price target of $94.09 based on the ratings of 23 analysts. The high is $140 issued by Piper Sandler on January 13, 2025. The low is $48 issued by Wedbush on January 13, 2025. The 3 most-recent analyst ratings were released by Piper Sandler, Cantor Fitzgerald, and HC Wainwright & Co. on March 17, 2025, February 26, 2025, and February 18, 2025, respectively. With an average price target of $109.33 between Piper Sandler, Cantor Fitzgerald, and HC Wainwright & Co., there's an implied 184.98% upside for Ultragenyx Pharmaceutical Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Cantor Fitzgerald
HC Wainwright & Co.
Canaccord Genuity
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Ultragenyx Pharmaceutical
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/17/2025 | Buy Now | 199.75% | Piper Sandler | Allison Bratzel65% | $140 → $115 | Maintains | Overweight | Get Alert |
| 02/26/2025 | Buy Now | 207.57% | Cantor Fitzgerald | Kristen Kluska70% | $118 → $118 | Reiterates | Overweight → Overweight | Get Alert |
| 02/18/2025 | Buy Now | 147.62% | HC Wainwright & Co. | Ed Arce62% | $95 → $95 | Reiterates | Buy → Buy | Get Alert |
| 02/18/2025 | Buy Now | 254.49% | Canaccord Genuity | Whitney Ijem46% | $121 → $136 | Maintains | Buy | Get Alert |
| 02/14/2025 | Buy Now | 147.62% | HC Wainwright & Co. | Ed Arce62% | $95 → $95 | Reiterates | Buy → Buy | Get Alert |
| 01/22/2025 | Buy Now | 207.57% | Cantor Fitzgerald | Kristen Kluska70% | $118 → $118 | Reiterates | Overweight → Overweight | Get Alert |
| 01/13/2025 | Buy Now | 264.92% | Piper Sandler | Christopher Raymond57% | $135 → $140 | Maintains | Overweight | Get Alert |
| 01/13/2025 | Buy Now | 25.11% | Wedbush | Laura Chico48% | $46 → $48 | Reiterates | Neutral → Neutral | Get Alert |
| 12/24/2024 | Buy Now | 147.62% | HC Wainwright & Co. | Ed Arce62% | $95 → $95 | Reiterates | Buy → Buy | Get Alert |
| 12/20/2024 | Buy Now | 129.38% | Wells Fargo | Tiago Fauth42% | $75 → $88 | Maintains | Overweight | Get Alert |
| 11/21/2024 | Buy Now | 165.87% | JP Morgan | Anupam Rama60% | $105 → $102 | Maintains | Overweight | Get Alert |
| 11/12/2024 | Buy Now | 215.39% | Canaccord Genuity | Whitney Ijem46% | $121 → $121 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | 215.39% | Canaccord Genuity | Whitney Ijem46% | $109 → $121 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | 100.7% | RBC Capital | Luca Issi42% | $77 → $77 | Reiterates | Outperform → Outperform | Get Alert |
| 11/06/2024 | Buy Now | 202.36% | Cantor Fitzgerald | Kristen Kluska70% | $116 → $116 | Reiterates | Overweight → Overweight | Get Alert |
| 11/06/2024 | Buy Now | 147.62% | HC Wainwright & Co. | Ed Arce62% | $82 → $95 | Maintains | Buy | Get Alert |
| 10/22/2024 | Buy Now | 202.36% | Cantor Fitzgerald | Kristen Kluska70% | $116 → $116 | Reiterates | Overweight → Overweight | Get Alert |
| 10/21/2024 | Buy Now | 90.28% | TD Cowen | Yaron Werber35% | $61 → $73 | Maintains | Buy | Get Alert |
| 10/01/2024 | Buy Now | 202.36% | Cantor Fitzgerald | Kristen Kluska70% | $116 → $116 | Reiterates | Overweight → Overweight | Get Alert |
| 09/26/2024 | Buy Now | 100.7% | RBC Capital | Luca Issi42% | $77 → $77 | Reiterates | Outperform → Outperform | Get Alert |
| 09/20/2024 | Buy Now | 202.36% | Cantor Fitzgerald | Kristen Kluska70% | $116 → $116 | Reiterates | Overweight → Overweight | Get Alert |
| 09/16/2024 | Buy Now | 202.36% | Cantor Fitzgerald | Kristen Kluska70% | $116 → $116 | Reiterates | Overweight → Overweight | Get Alert |
| 08/05/2024 | Buy Now | 111.13% | Barclays | Gena Wang51% | $83 → $81 | Maintains | Overweight | Get Alert |
| 08/02/2024 | Buy Now | 95.49% | Wells Fargo | Tiago Fauth42% | $72 → $75 | Maintains | Overweight | Get Alert |
| 08/02/2024 | Buy Now | 98.1% | Goldman Sachs | Salveen Richter53% | $67 → $76 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | 202.36% | Cantor Fitzgerald | Kristen Kluska70% | $115 → $116 | Maintains | Overweight | Get Alert |
| 08/02/2024 | Buy Now | 19.9% | Wedbush | Laura Chico48% | $43 → $46 | Maintains | Neutral | Get Alert |
| 07/23/2024 | Buy Now | 189.33% | Canaccord Genuity | Whitney Ijem46% | $111 → $111 | Maintains | Buy | Get Alert |
| 07/22/2024 | Buy Now | 199.75% | Cantor Fitzgerald | Kristen Kluska70% | $115 → $115 | Reiterates | Overweight → Overweight | Get Alert |
| 07/18/2024 | Buy Now | 17.29% | Wedbush | Laura Chico48% | $45 → $45 | Reiterates | Neutral → Neutral | Get Alert |
| 06/12/2024 | Buy Now | 199.75% | Cantor Fitzgerald | Kristen Kluska70% | $115 → $115 | Reiterates | Overweight → Overweight | Get Alert |
| 06/06/2024 | Buy Now | 74.64% | Goldman Sachs | Salveen Richter53% | $56 → $67 | Upgrade | Neutral → Buy | Get Alert |
| 05/31/2024 | Buy Now | 25.11% | Wedbush | Laura Chico48% | $47 → $48 | Maintains | Neutral | Get Alert |
| 05/31/2024 | Buy Now | 98.1% | B of A Securities | Tazeen Ahmad56% | $83 → $76 | Maintains | Buy | Get Alert |
| 05/31/2024 | Buy Now | 189.33% | Canaccord Genuity | Whitney Ijem46% | $109 → $111 | Maintains | Buy | Get Alert |
| 05/31/2024 | Buy Now | 199.75% | Cantor Fitzgerald | Kristen Kluska70% | $107 → $115 | Maintains | Overweight | Get Alert |
| 05/31/2024 | Buy Now | 231.03% | Stifel | Dae Gon Ha48% | $124 → $127 | Maintains | Buy | Get Alert |
| 05/31/2024 | Buy Now | 87.67% | Baird | Joel Beatty69% | $68 → $72 | Maintains | Outperform | Get Alert |
| 05/06/2024 | Buy Now | 184.11% | Canaccord Genuity | Whitney Ijem46% | $111 → $109 | Maintains | Buy | Get Alert |
| 05/03/2024 | Buy Now | 178.9% | Cantor Fitzgerald | Kristen Kluska70% | $107 → $107 | Reiterates | Overweight → Overweight | Get Alert |
| 05/03/2024 | Buy Now | 22.51% | Wedbush | Laura Chico48% | $48 → $47 | Maintains | Neutral | Get Alert |
| 04/24/2024 | Buy Now | 59% | TD Cowen | Yaron Werber35% | $59 → $61 | Maintains | Buy | Get Alert |
| 04/22/2024 | Buy Now | 100.7% | RBC Capital | Luca Issi42% | → $77 | Initiates | → Outperform | Get Alert |
| 04/17/2024 | Buy Now | 25.11% | Wedbush | Laura Chico48% | $48 → $48 | Reiterates | Neutral → Neutral | Get Alert |
| 04/16/2024 | Buy Now | 25.11% | Wedbush | Laura Chico48% | $48 → $48 | Reiterates | Neutral → Neutral | Get Alert |
| 04/05/2024 | Buy Now | 178.9% | Cantor Fitzgerald | Kristen Kluska70% | $107 → $107 | Reiterates | Overweight → Overweight | Get Alert |
| 03/18/2024 | Buy Now | 139.8% | JP Morgan | Anupam Rama60% | $88 → $92 | Maintains | Overweight | Get Alert |
| 02/27/2024 | Buy Now | 178.9% | Cantor Fitzgerald | Kristen Kluska70% | $107 → $107 | Reiterates | Overweight → Overweight | Get Alert |
| 02/27/2024 | Buy Now | 129.38% | JP Morgan | Cory Kasimov69% | $84 → $88 | Maintains | Overweight | Get Alert |
| 02/21/2024 | Buy Now | 189.33% | Canaccord Genuity | Whitney Ijem46% | $110 → $111 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | 25.11% | Wedbush | Laura Chico48% | $47 → $48 | Maintains | Neutral | Get Alert |
| 02/15/2024 | Buy Now | 197.15% | Cantor Fitzgerald | Kristen Kluska70% | $114 → $114 | Reiterates | Overweight → Overweight | Get Alert |
| 01/30/2024 | Buy Now | 77.24% | Baird | Joel Beatty69% | $57 → $68 | Maintains | Outperform | Get Alert |
| 01/19/2024 | Buy Now | 197.15% | Cantor Fitzgerald | Kristen Kluska70% | $114 → $114 | Reiterates | Overweight → Overweight | Get Alert |
| 12/08/2023 | Buy Now | 87.67% | Wells Fargo | Tiago Fauth42% | → $72 | Initiates | → Overweight | Get Alert |
| 11/03/2023 | Buy Now | 118.95% | Morgan Stanley | Jeffrey Hung55% | $90 → $84 | Maintains | Overweight | Get Alert |
| 10/25/2023 | Buy Now | 238.85% | Piper Sandler | Christopher Raymond57% | $135 → $130 | Maintains | Overweight | Get Alert |
| 10/10/2023 | Buy Now | 134.59% | Morgan Stanley | Jeffrey Hung55% | $95 → $90 | Maintains | Overweight | Get Alert |
| 09/25/2023 | Buy Now | 197.15% | Cantor Fitzgerald | Kristen Kluska70% | → $114 | Reiterates | Overweight → Overweight | Get Alert |
| 08/04/2023 | Buy Now | 147.62% | Morgan Stanley | Jeffrey Hung55% | $95 → $95 | Reiterates | Overweight → Overweight | Get Alert |
| 08/01/2023 | Buy Now | 113.74% | HC Wainwright & Co. | Ed Arce62% | → $82 | Reiterates | Buy → Buy | Get Alert |
| 06/14/2023 | Buy Now | 150.23% | Credit Suisse | Tiago Fauth42% | → $96 | Assumes | → Outperform | Get Alert |
| 06/07/2023 | Buy Now | 246.67% | Citigroup | Yigal Nochomovitz55% | $130 → $133 | Maintains | Buy | Get Alert |
| 06/06/2023 | Buy Now | 108.52% | Evercore ISI Group | Liisa Bayko70% | $60 → $80 | Upgrade | In-Line → Outperform | Get Alert |
| 06/06/2023 | Buy Now | 32.93% | Wedbush | Laura Chico48% | $48 → $51 | Maintains | Neutral | Get Alert |
| 05/08/2023 | Buy Now | 25.11% | Wedbush | Laura Chico48% | $47 → $48 | Maintains | Neutral | Get Alert |
| 05/05/2023 | Buy Now | 238.85% | Citigroup | Yigal Nochomovitz55% | $130 → $130 | Maintains | Buy | Get Alert |
| 05/05/2023 | Buy Now | 150.23% | Credit Suisse | Tiago Fauth42% | → $96 | Reiterates | → Outperform | Get Alert |
| 04/26/2023 | Buy Now | 197.15% | Cantor Fitzgerald | Kristen Kluska70% | → $114 | Initiates | → Overweight | Get Alert |
| 03/18/2023 | Buy Now | 238.85% | Citigroup | Yigal Nochomovitz55% | $135 → $130 | Maintains | Buy | Get Alert |
| 02/17/2023 | Buy Now | 150.23% | Credit Suisse | Tiago Fauth42% | → $96 | Reiterates | → Outperform | Get Alert |
| 02/17/2023 | Buy Now | 48.57% | Baird | Joel Beatty69% | $50 → $57 | Maintains | Outperform | Get Alert |
| 02/03/2023 | Buy Now | 147.62% | Morgan Stanley | Jeffrey Hung55% | $100 → $95 | Maintains | Overweight | Get Alert |
| 01/18/2023 | Buy Now | 134.59% | Canaccord Genuity | Whitney Ijem46% | → $90 | Assumes | → Buy | Get Alert |
| 01/09/2023 | Buy Now | 251.88% | Citigroup | Yigal Nochomovitz55% | $138 → $135 | Maintains | Buy | Get Alert |
| 12/30/2022 | Buy Now | 113.74% | HC Wainwright & Co. | Ed Arce62% | → $82 | Assumes | → Buy | Get Alert |
| 11/04/2022 | Buy Now | 43.36% | Goldman Sachs | Salveen Richter53% | $74 → $55 | Maintains | Neutral | Get Alert |
| 11/03/2022 | Buy Now | 259.7% | Citigroup | Yigal Nochomovitz55% | $142 → $138 | Maintains | Buy | Get Alert |
| 11/03/2022 | Buy Now | 160.65% | Morgan Stanley | Jeffrey Hung55% | $109 → $100 | Maintains | Overweight | Get Alert |
| 11/03/2022 | Buy Now | 181.51% | SVB Leerink | Joseph Schwartz50% | $115 → $108 | Maintains | Outperform | Get Alert |
| 11/03/2022 | Buy Now | 150.23% | Credit Suisse | Tiago Fauth42% | $105 → $96 | Maintains | Outperform | Get Alert |
| 11/03/2022 | Buy Now | 30.33% | Baird | Joel Beatty69% | $63 → $50 | Upgrade | Neutral → Outperform | Get Alert |
| 10/13/2022 | Buy Now | 30.33% | Guggenheim | Debjit Chattopadhyay54% | → $50 | Upgrade | Neutral → Buy | Get Alert |
| 08/02/2022 | Buy Now | 270.13% | Citigroup | Yigal Nochomovitz55% | $146 → $142 | Maintains | Buy | Get Alert |
| 08/01/2022 | Buy Now | 56.39% | Evercore ISI Group | Liisa Bayko70% | $95 → $60 | Downgrade | Outperform → In-Line | Get Alert |
| 07/29/2022 | Buy Now | 238.85% | Piper Sandler | Christopher Raymond57% | $135 → $130 | Maintains | Overweight | Get Alert |
| 07/01/2022 | Buy Now | 270.13% | Stifel | Dae Gon Ha48% | $176 → $142 | Maintains | Buy | Get Alert |
| 05/24/2022 | Buy Now | 163.26% | Goldman Sachs | — | $139 → $101 | Maintains | Neutral | Get Alert |
| 05/19/2022 | Buy Now | 251.88% | Piper Sandler | Christopher Raymond57% | $170 → $135 | Maintains | Overweight | Get Alert |
| 05/10/2022 | Buy Now | 280.56% | Citigroup | Yigal Nochomovitz55% | $150 → $146 | Maintains | Buy | Get Alert |
| 05/06/2022 | Buy Now | 184.11% | Morgan Stanley | Jeffrey Hung55% | $118 → $109 | Maintains | Overweight | Get Alert |
| 05/06/2022 | Buy Now | 199.75% | SVB Leerink | Joseph Schwartz50% | $178 → $115 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Ultragenyx Pharmaceutical (RARE) stock?
The latest price target for Ultragenyx Pharmaceutical (NASDAQ:RARE) was reported by Piper Sandler on March 17, 2025. The analyst firm set a price target for $115.00 expecting RARE to rise to within 12 months (a possible 199.75% upside). 46 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ultragenyx Pharmaceutical (RARE)?
The latest analyst rating for Ultragenyx Pharmaceutical (NASDAQ:RARE) was provided by Piper Sandler, and Ultragenyx Pharmaceutical maintained their overweight rating.
When was the last upgrade for Ultragenyx Pharmaceutical (RARE)?
The last upgrade for Ultragenyx Pharmaceutical Inc happened on June 6, 2024 when Goldman Sachs raised their price target to $67. Goldman Sachs previously had a neutral for Ultragenyx Pharmaceutical Inc.
When was the last downgrade for Ultragenyx Pharmaceutical (RARE)?
The last downgrade for Ultragenyx Pharmaceutical Inc happened on August 1, 2022 when Evercore ISI Group changed their price target from $95 to $60 for Ultragenyx Pharmaceutical Inc.
When is the next analyst rating going to be posted or updated for Ultragenyx Pharmaceutical (RARE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ultragenyx Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ultragenyx Pharmaceutical was filed on March 17, 2025 so you should expect the next rating to be made available sometime around March 17, 2026.
Is the Analyst Rating Ultragenyx Pharmaceutical (RARE) correct?
While ratings are subjective and will change, the latest Ultragenyx Pharmaceutical (RARE) rating was a maintained with a price target of $140.00 to $115.00. The current price Ultragenyx Pharmaceutical (RARE) is trading at is $38.37, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.